A Phase 2 interventional study of Elinzanetant and Placebo in Sleep Disturbances Associated With Menopause, sponsored by Bayer. Completed at 40 sites in 7 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause.
Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life.
The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances.
The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo.
For this, the researchers will analyze
The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks.
Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned.
During the study, the doctors and their study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take Elinzanetant
Drug: Elinzanetant
Participants will take elinzanetant matching placebo
Other: Placebo
Oral
Oral
Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)
WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.
Time frame: From baseline until week 4
Change From Baseline in WASO at Week 12 as Measured by PSG
WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.
Time frame: From baseline until week 12
Change From Baseline in Sleep Efficiency (SE) at Week 4 as Measured by PSG
Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.
Time frame: From baseline to Week 4
Change From Baseline in SE at Week 12 as Measured by PSG
Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.
Time frame: From baseline to week 12
Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 4
Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.
Time frame: From baseline until week 4
Change From Baseline inPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 12
Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.
Time frame: From baseline until week 12
Change From Baseline in Insomnia Severity Index (ISI) Total Score at Week 4
Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.
Time frame: From baseline until week 4
Change From Baseline in ISI Total Score at Week 12
Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.
Time frame: From baseline until week 12
The study was conducted at 39 study centers, of which 30 centers had randomized participants in Europe and the US. In the US, separate sleep laboratories were used by 9 sites that did not have polysomnography (PSG) capability.
| Milestone | Elinzanetant | Placebo |
|---|---|---|
| Started | 55 | 55 |
| Completed | 52 | 51 |
| Not completed | 3 | 4 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Subject took an out of state job and had to early terminate | 1 | 0 |
| Withdrew: Adverse event | 2 | 2 |
WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.
| Minutes | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG) | -23.50 ± 4.63 | -1.01 ± 4.68 |
WASO is defined as total time (min) spent awake from onset of persistent sleep to lights on. Persistent sleep is defined as 20 consecutive epochs (10 min) of non wakefulness. Smaller WASO values indicate shorter periods of wakefulness after sleep onset.
| Minutes | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in WASO at Week 12 as Measured by PSG | -16.48 ± 4.64 | -15.54 ± 4.76 |
Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.
| Percentage | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in Sleep Efficiency (SE) at Week 4 as Measured by PSG | 6.85 ± 8.07 | 1.13 ± 10.31 |
Sleep efficiency is defined as the percentage of time spent asleep while in bed. (Total sleep time / time in bed) x 100. Higher sleep efficiency values indicate more time spent asleep.
| Percentage | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in SE at Week 12 as Measured by PSG | 5.15 ± 9.68 | 4.67 ± 8.10 |
Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.
| T-Score | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 4 | -11.17 ± 8.04 | -6.59 ± 6.76 |
Participants' responses to the 8 items of the instrument are scored on a 1-5 numeric rating scale and will be aggregated to derive total raw scores ranging from 8-40 with higher scores indicating greater severity of sleep disturbance. These total raw scores will be converted into T-scores for comparison with population norms (United States general population). T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population.
| T-Score | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline inPatient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score at Week 12 | -14.66 ± 9.36 | -6.65 ± 8.29 |
Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.
| Scores on a scale | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in Insomnia Severity Index (ISI) Total Score at Week 4 | -7.8 ± 6.0 | -4.7 ± 4.8 |
Insomnia Severity Index (ISI): The ISI is a 7-item tool that measures insomnia severity over the past two weeks (Bastien et al., 2001). It evaluates sleep onset, maintenance issues, early morning awakenings, satisfaction with sleep, noticeability of problems, distress caused, and daytime interference. Scoring: The ISI uses a 5-point Likert scale (0 to 4). Item scores are summed to yield a total score ranging from 0 to 28. Severity Categories: 0-7: No clinically significant insomnia (better outcome) 8-14: Subthreshold insomnia (moderate outcome) 15-21: Clinical insomnia (moderate severity) (worse outcome) 22-28: Clinical insomnia (severe) (worse outcome) Interpretation: Higher total scores indicate worse insomnia severity, while lower scores indicate better sleep quality. The total score is the sum of individual item scores.
| ISI total score | Elinzanetant | Placebo |
|---|---|---|
| Change From Baseline in ISI Total Score at Week 12 | -9.8 ± 6.4 | -6.9 ± 5.6 |
Collected over After the first study intervention up to 113 days until the last follow-up visit. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BAY 3427080 / Elinzanetant | 0/55 (0%) | 0/55 (0%) | 24/55 (43.6%) |
| Placebo | 0/55 (0%) | 2/55 (3.6%) | 25/55 (45.5%) |
| Event | BAY 3427080 / Elinzanetant | Placebo |
|---|---|---|
| DiverticulitisInfections and infestations | 0/55 | 1/55 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/55 | 1/55 |
| Event | BAY 3427080 / Elinzanetant | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 5/55 | 6/55 |
| FatigueGeneral disorders | 4/55 | 0/55 |
| GastroenteritisInfections and infestations | 0/55 | 3/55 |
| Abdominal pain upperGastrointestinal disorders | 2/55 | 1/55 |
| Urinary tract infectionInfections and infestations | 2/55 | 0/55 |
| COVID-19Infections and infestations | 1/55 | 2/55 |
| Alanine aminotransferase increasedInvestigations | 0/55 | 2/55 |
| Gamma-glutamyltransferase increasedInvestigations | 0/55 | 2/55 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/55 | 1/55 |
| Back painMusculoskeletal and connective tissue disorders | 2/55 | 0/55 |
| Age, Continuous(Years) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| Mean | 54.8 ± 4.6 | 54.9 ± 4.7 | 54.8 ± 4.6 |
| Sex/Gender, Customized(Participants) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| Female | 55 | 55 | 110 |
| Race (NIH/OMB)(Participants) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 14 | 9 | 23 |
| White | 40 | 45 | 85 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Weight (kg)(Kilograms) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| Mean | 75.77 ± 12.45 | 74.41 ± 10.61 | 75.09 ± 11.53 |
| Height (cm)(Centimeters) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| Mean | 164.64 ± 7.08 | 164.18 ± 7.01 | 164.41 ± 7.02 |
| Body Mass Index (kg/m2)(Kilogram per square meter) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| Mean | 27.97 ± 4.36 | 27.63 ± 3.75 | 27.80 ± 4.05 |
| Average weekly frequency of moderate to severe HF(Participants) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| <35 moderate to severe HF per week | 13 | 11 | 24 |
| >=35 - <50 moderate to severe HF per week | 11 | 13 | 24 |
| >=50 moderate to severe HF per week | 31 | 31 | 62 |
| Smoking(Participants) | Elinzanetant | Placebo | Total |
|---|---|---|---|
| Never | 40 | 42 | 82 |
| Former | 5 | 10 | 15 |
| Current | 10 | 3 | 13 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Nov 2023 to primary completion in Aug 2024, 9 months.
Results were first posted in Nov 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elinzanetant